Comparing GLP-1 peptides: mono, dual, triple and glucagon

Research context (RUO): This hub compares the incretin peptides (GLP-1 and related agonists) studied in research on metabolism and weight. All substances mentioned are supplied solely for in-vitro laboratory research and are not intended for human or animal use.

Comparing GLP-1 peptides: mono, dual, triple and glucagon

The GLP-1 family is growing fast, and it is easy to miss the wood for the trees. The key is simple: it comes down to on how many hormone receptors one molecule works at a time. From one receptor (mono) to two (dual) to three (triple) — and each step is associated with a greater effect in studies. This page is an overview (hub): we place the generations side by side and refer to the separate pillar per peptide.

The receptors in brief

After a meal, the intestines release hormones that regulate metabolism. Three are important here: GLP-1 (satiety, slower gastric emptying), GIP (co-regulator of the insulin response) and glucagon (which affects energy expenditure and liver metabolism). A molecule that activates one or more of these receptors is called an agonist. The more receptors, the broader the metabolic effect in research.

The generations in one table

Mono — the basis

Semaglutide acts on one receptor (GLP-1) and is the benchmark against which the rest are measured. Liraglutide is the daily predecessor from the same class.

Dual — two pathways

Tirzepatide adds GIP to GLP-1, while survodutide combines GLP-1 with glucagon (and is studied mainly around liver fat). A direct comparison of the first two generations is in semaglutide vs tirzepatide.

Triple & combinations

Retatrutide targets all three receptors (GIP, GLP-1, glucagon). In addition, there are combinations such as CagriSema — semaglutide plus the amylin analogue cagrilintide. The full three-way comparison is in Retatrutide vs tirzepatide vs semaglutide.

Quality & purity

Every relevant batch is independently HPLC-tested by an external laboratory; the CoA is publicly verifiable per batch. See also why we rejected a batch.

What the studies show side by side

Receptor profiles say something about the mechanism, but not automatically about the outcome. Below is the strongest weight change published so far per generation. Important: trial durations and participant groups differ, so this is an order of magnitude and not a ranking.

The first two rows come from the same head-to-head trial and are therefore mutually comparable; the third comes from a separate phase 2 trial with a shorter duration. More detail is in semaglutide vs tirzepatide and retatrutide research.

Amylin: the route alongside the incretin system

All of the peptides above act through incretin receptors. Amylin analogues do something different: they mimic the hormone amylin, which is released together with insulin from the beta cells and drives satiety through its own route in the brainstem. Because that mechanism works alongside rather than instead of GLP-1, research looks mainly at combinations. Cagrilintide with semaglutide is the best-known example; petrelintide, eloralintide and bioglutide are at earlier stages.

The full comparison of both classes is in amylin versus incretin.

Oral or injectable?

Peptides normally survive the gastrointestinal tract poorly: stomach acid and enzymes break down the chain before anything reaches the bloodstream. Semaglutide is so far the only incretin peptide with an oral form that gets around this problem, thanks to an excipient that locally improves uptake in the stomach wall. Bioavailability nonetheless remains low, which explains why oral doses are ten to a hundred times higher than injectable ones. For laboratory research this matters mainly because lyophilised peptide for research is always based on the injectable form.

How do you choose a comparison point in research?

Anyone placing two peptides side by side in an RUO context quickly runs into three pitfalls. The first is dose equivalence: 1 mg of retatrutide is not the same as 1 mg of semaglutide, because receptor affinity differs per compound. The second is duration, because with all incretins the curves only separate after thirty to forty weeks. The third is the titration schedule: almost every protocol builds the dose up in steps, and a comparison at endpoint without an equal build-up schedule says little. Line those three up and a usable comparison remains.

Frequently asked questions

What is the difference between mono, dual and triple?
The number of receptors a peptide activates at once: one (mono, e.g. semaglutide), two (dual, e.g. tirzepatide) or three (triple, retatrutide). In studies, each additional receptor is accompanied by a greater metabolic effect.

What does glucagon do in this context?
Glucagon activation is associated in research with higher energy expenditure and fat breakdown in the liver. Survodutide (GLP-1 + glucagon) and retatrutide (triple) make use of this.

Which is the strongest?
In published studies, retatrutide reported the highest figures, but the studies differ in design and phase. “Newer” or “stronger in one trial” does not automatically mean better for every research goal.

What is CagriSema?
A combination of semaglutide and the amylin analogue cagrilintide, acting on two different metabolic pathways.

May I use these peptides?
No. All GLP-1 and related peptides are intended solely for in-vitro laboratory research (RUO), not for humans or animals.

Read more & research at Peplife

• View all metabolism peptides
• Mono: semaglutide · liraglutide
• Dual: tirzepatide · survodutide
• Triple & combinations: retatrutide · cagrilintide · CagriSema
• Comparisons: semaglutide vs tirzepatide · Retatrutide vs tirzepatide vs semaglutide

Sources: Retatrutide phase 2, NEJM 2023 · SURMOUNT-1 (tirzepatide), NEJM 2022 · STEP 1 (semaglutide), NEJM 2021

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.